TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 29273079

Group type: EXPERIMENTAL
Intervention: Early Structured Physiotherapy with an intra-articular steroid injection
Number of subjects: 500

Group type: COMPARATOR
Intervention: Manipulation under anaesthesia with a steroid injection
Number of subjects: 500

Group type: COMPARATOR
Intervention: Arthroscopic capsular release followed by manipulation
Number of subjects: 500
Study: 27084728

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 5 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 1.25 μg once daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tiotropium Respimat 2.5 μg once daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Tiotropium HandiHaler 18 μg once daily
Number of subjects: 0
Study: 24332420

Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stents (EES)
Number of subjects: 2013

Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Paclitaxel-eluting stents (PES)
Number of subjects: 2013

Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Endeavor Sprint stents (ZES-S)
Number of subjects: 2013
Study: 21948942

Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab 80 mg at baseline followed by 40 mg every other week for 1 year
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intravenous infliximab 5 mg/kg
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Subcutaneous adalimumab
Number of subjects: 73

Group type: COMPARATOR
Intervention: Intravenous infliximab
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 73
Study: 19323050

Group type: EXPERIMENTAL
Intervention: Self-help group program for 16 weeks
Number of subjects: 146

Group type: COMPARATOR
Intervention: Diabetic services (Control)
Number of subjects: 146
Study: 17270002

Group type: EXPERIMENTAL
Intervention: Tegaserod 6 mg b.d.
Number of subjects: 250

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 250
Study: 16113029

Group type: EXPERIMENTAL
Intervention: Chinese herbal medicine combined with chemotherapy
Number of subjects: 2079
Study: 11932879

Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CSA)
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 57

Group type: COMPARATOR
Intervention: Combination therapy (CSA and MTX)
Number of subjects: 57
Study: 9474925

Group type: EXPERIMENTAL
Intervention: IL-3 at a dose of 5 micrograms/kg/day for 7 to 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: IL-11 at a dose of 50 micrograms/kg/day for 14 days
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Thrombopoietin (TPO)
Number of subjects: 0
Study: 7535834

Group type: EXPERIMENTAL
Intervention: Single aural toilet and instillation of medicated ointment
Number of subjects: 0

Group type: COMPARATOR
Intervention: Regular aural toilet and medicated dressings
Number of subjects: 0
Study: 2709485

Group type: EXPERIMENTAL
Intervention: Trivalent oral polio vaccine (TOPV), 5 doses at intervals of 4 weeks
Number of subjects: 62

Group type: COMPARATOR
Intervention: Trivalent oral polio vaccine (TOPV), 2 doses
Number of subjects: 62

Group type: COMPARATOR
Intervention: Trivalent oral polio vaccine (TOPV), 3 doses
Number of subjects: 62
Study: 779704

Group type: EXPERIMENTAL
Intervention: Thioridazine hydrochloride (15% to 50% of pretrial dose) combined with metyrosine
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Metyrosine
Number of subjects: 4
Study: 31349690

Group type: EXPERIMENTAL
Intervention: Polygonatum sibiricum (PS) rhizome extract (500 mg/day, n = 40)
Number of subjects: 80

Group type: COMPARATOR
Intervention: Placebo (n = 40)
Number of subjects: 80
Study: 28848126

Group type: EXPERIMENTAL
Intervention: Crossover group in the taxane group
Number of subjects: 618

Group type: COMPARATOR
Intervention: Protocol-recommended group in the taxane group
Number of subjects: 618

Group type: COMPARATOR
Intervention: Other chemotherapy group in the taxane group
Number of subjects: 618

Group type: EXPERIMENTAL
Intervention: S-1 group
Number of subjects: 618
Study: 26079661

Group type: EXPERIMENTAL
Intervention: Enhanced oral healthcare
Number of subjects: 400

Group type: COMPARATOR
Intervention: Usual oral healthcare
Number of subjects: 400
Study: 23483541

Group type: EXPERIMENTAL
Intervention: ENB 2.0 (external neck brace)
Number of subjects: 20

Group type: COMPARATOR
Intervention: ENB 1.0 (previous model of external neck brace)
Number of subjects: 20
Study: 21644471

Group type: EXPERIMENTAL
Intervention: C- ROM (Clarithromycin, Rifampicin, Ofloxacin, Minocycline)
Number of subjects: 300

Group type: COMPARATOR
Intervention: ROM (Rifampicin, Ofloxacin, Minocycline)
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: C- ROM
Number of subjects: 300

Group type: COMPARATOR
Intervention: ROM
Number of subjects: 300
Study: 19506839

Group type: COMPARATOR
Intervention: 0.125 mg pramipexole
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.1875 mg pramipexole
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.1 mg/kg pramipexole
Number of subjects: 20

Group type: COMPARATOR
Intervention: 0.3 mg/kg pramipexole
Number of subjects: 20

Group type: COMPARATOR
Intervention: 1.0 mg/kg pramipexole
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study: 16686721

Group type: EXPERIMENTAL
Intervention: 15 mg GYKI‐16084
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: 7.5 mg GYKI‐16084
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 14977342

Group type: EXPERIMENTAL
Intervention: Propofol (Group P)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Propofol for induction and sevoflurane for maintenance (Group P/S)
Number of subjects: 96

Group type: COMPARATOR
Intervention: Sevoflurane (Group S)
Number of subjects: 96
Study: 14588230

Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 30

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 30
Study: 10559610

Group type: EXPERIMENTAL
Intervention: Radical nephrectomy with complete lymph node dissection
Number of subjects: 772

Group type: COMPARATOR
Intervention: Radical nephrectomy alone
Number of subjects: 772

Group type: EXPERIMENTAL
Intervention: Complete lymph node dissection
Number of subjects: 772
Study: 7774535

Group type: EXPERIMENTAL
Intervention: Rolled oats (muesli)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Boiled rolled oats (oat porridge)
Number of subjects: 9

Group type: COMPARATOR
Intervention: White wheat bread
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Boiled intact oat kernels (kernel porridge)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Boiled intact wheat kernels (kernel porridge)
Number of subjects: 9
Study: 2183873

Group type: EXPERIMENTAL
Intervention: Didox 6 g m‐2 by 36 h infusion
Number of subjects: 12

Group type: COMPARATOR
Intervention: Didox 6 g m‐2 by 30 min infusion
Number of subjects: 12
Study: 7463326

Group type: EXPERIMENTAL
Intervention: 1 mg of dexamethasone at 11 pm (Treatment A)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 2 mg of dexamethasone at 11 pm (Treatment B)
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: 1 mg of dexamethasone at 11 pm and an additional 1 mg at 6 am (Treatment C)
Number of subjects: 9
Study: 31985138

Group type: EXPERIMENTAL
Intervention: Health Belief Model (HBM)‐based health education programme
Number of subjects: 30
Study: 29170998

Group type: EXPERIMENTAL
Intervention: Isotonic maintenance fluid (NaCl 0.9% in glucose 5% with 40 mmol L‐1 potassium chloride)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Hypotonic maintenance fluid (premixed solution containing 54 mmol L‐1 sodium, 55 mmol L‐1 chloride and 26 mmol of potassium)
Number of subjects: 68
Study: 25701156

Group type: EXPERIMENTAL
Intervention: Simplified informed consent form (features include plain language, short sentences, diagrams, pictures, and bullet points)
Number of subjects: 150

Group type: COMPARATOR
Intervention: Standard informed consent form
Number of subjects: 150
Study: 23816316

Group type: EXPERIMENTAL
Intervention: Walking intervention group
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waiting list control group
Number of subjects: 0
Study: 22068990

Group type: EXPERIMENTAL
Intervention: Surgery (EC-IC bypass surgery)
Number of subjects: 195

Group type: COMPARATOR
Intervention: No surgery (best medical therapy)
Number of subjects: 195
Study: 19360858

Group type: EXPERIMENTAL
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 2381

Group type: COMPARATOR
Intervention: Bare-metal stent (BMS)
Number of subjects: 2381
Study: 16905810

Group type: EXPERIMENTAL
Intervention: Curiosin and plasma-therapy
Number of subjects: 130

Group type: COMPARATOR
Intervention: Traditional treatment (control group)
Number of subjects: 130
Study: 15688984

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate (MgSO4) treatment at a dose of 4 g/day i.v. for the first 24 hours after admission
Number of subjects: 0

Group type: COMPARATOR
Intervention: Conventional therapy without MgSO4
Number of subjects: 0
Study: 11343038

Group type: EXPERIMENTAL
Intervention: Intravenous secretin (2.0 clinical units per kg as a single dose)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo (normal saline solution)
Number of subjects: 60
Study: 9389261

Group type: EXPERIMENTAL
Intervention: suxamethonium 1.0 mg kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: rocuronium 0.9 mg kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: mivacurium 0.1 mg kg-1 with rocuronium 0.3 mg kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: mivacurium 0.15 mg kg-1 with rocuronium 0.45 mg kg-1
Number of subjects: 120

Group type: COMPARATOR
Intervention: mivacurium 0.2 mg kg-1
Number of subjects: 120

Group type: COMPARATOR
Intervention: rocuronium 0.6 mg kg-1
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: rocuronium 0.45 mg kg-1 and mivacurium 0.15 mg kg-1
Number of subjects: 120
Study: 7893583

Group type: EXPERIMENTAL
Intervention: Idrapril calcium 100 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idrapril calcium 200 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idrapril calcium 400 mg twice daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Idrapril calcium (all doses)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 30348220

Group type: EXPERIMENTAL
Intervention: Mastery Approach to Coaching (MAC) program
Number of subjects: 293

Group type: COMPARATOR
Intervention: Control group (no MAC program)
Number of subjects: 293
Study: 27513402

Group type: EXPERIMENTAL
Intervention: Kinesiotaping (KT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo Kinesiotaping (KT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Orthotic Device (OD)
Number of subjects: 0
Study: 24508475

Group type: EXPERIMENTAL
Intervention: Early dialysis initiation (eGFR at initiation ≥10mL/min/1.73m(2))
Number of subjects: 652

Group type: COMPARATOR
Intervention: Later dialysis initiation (eGFR < 10mL/min/1.73m(2))
Number of subjects: 652
Study: 22591121

Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg once daily
Number of subjects: 343

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 343

Group type: EXPERIMENTAL
Intervention: Esomeprazole
Number of subjects: 343
Study: 21054991

Group type: EXPERIMENTAL
Intervention: AcrySof IQ ReSTOR IOL (SN6AD3)
Number of subjects: 50

Group type: COMPARATOR
Intervention: AcrySof IQ IOL (SN60WF)
Number of subjects: 50
Study: 17906871

Group type: EXPERIMENTAL
Intervention: Sildenafil (50 mg) plus visual sexual stimulation (VSS)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Placebo plus visual sexual stimulation (VSS)
Number of subjects: 11
Study: 16827862

Group type: EXPERIMENTAL
Intervention: Tac/Mycophenolate Mofetil (MMF)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Tac/Sirolimus (SRL)
Number of subjects: 82
Study: 12839049

Group type: EXPERIMENTAL
Intervention: Thrombolysis (streptokinase or rt-PA)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Primary percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Thrombolysis (TIMI flow 0/1)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (normal values)
Number of subjects: 60
Study: 10638606

Group type: EXPERIMENTAL
Intervention: Neostigmine 2.0 mg i.v. over 3-5 min
Number of subjects: 20

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neostigmine (open-label treatment)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Neostigmine
Number of subjects: 20
Study: 8800029

Group type: EXPERIMENTAL
Intervention: Reperfusion achieved by 60 minutes (group M1)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Reperfusion achieved by 130 minutes (group M2)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group M1 (Reperfusion at 60 minutes)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Group M2 (Reperfusion at 130 minutes)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Both groups (M1 and M2)
Number of subjects: 36
Study: 1473540

Group type: EXPERIMENTAL
Intervention: Ceftazidime + Ampicillin (CAZ + AMP)
Number of subjects: 1316

Group type: COMPARATOR
Intervention: Aminoglycoside + Ampicillin (AG + AMP)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Ceftazidime monotherapy (CAZ)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: Ceftazidime or Ceftazidime + Ampicillin (CAZ or CAZ + AMP)
Number of subjects: 1316

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 1316
Study: 6464961

Group type: EXPERIMENTAL
Intervention: Group type A behavior counseling in addition to group cardiologic counseling
Number of subjects: 862

Group type: COMPARATOR
Intervention: Group cardiologic counseling
Number of subjects: 862
Study: 31251546

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.045% lotion
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% cream
Number of subjects: 210

Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 210
Study: 30052230

Group type: EXPERIMENTAL
Intervention: Inhaled levosimendan administered 6th hourly over 24 h
Number of subjects: 50

Group type: EXPERIMENTAL
Intervention: Intravenous levosimendan infusion at 0.1 mcg/kg/min for 24 h
Number of subjects: 50

Group type: COMPARATOR
Intervention: Control group (not explicitly defined, but implied as the comparison between inhaled and intravenous levosimendan)
Number of subjects: 50
Study: 27352492

Group type: EXPERIMENTAL
Intervention: SHI's manipulation
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 108

Group type: COMPARATOR
Intervention: Artificial tears
Number of subjects: 108
Study: 24560584

Group type: EXPERIMENTAL
Intervention: Symbiotic Drink (administered via enteral feeding during the first 7 days)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 89
Study: 23189108

Group type: EXPERIMENTAL
Intervention: Intervention group (Students in the Hospital program)
Number of subjects: 760

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 760
Study: 19281535

Group type: EXPERIMENTAL
Intervention: Mannitol
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Haemofiltration
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control
Number of subjects: 45
Study: 17588310

Group type: EXPERIMENTAL
Intervention: Low frequency sensory nerve stimulation (LF‐SNS) for 12 weeks
Number of subjects: 66

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: LF‐SNS in responders
Number of subjects: 66
Study: 16376754

Group type: EXPERIMENTAL
Intervention: Pulsed-wave tissue Doppler (PW-TD) method
Number of subjects: 120

Group type: COMPARATOR
Intervention: Conventional pulsed-wave Doppler (PWD) method
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Both methods (PW-TD and PWD)
Number of subjects: 120
Study: 12271103

Group type: EXPERIMENTAL
Intervention: Presence of pets
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Presence of spouse
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Presence of friend (for non-pet owners)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Presence of spouse and pet/friend
Number of subjects: 240
Study: 9814627

Group type: EXPERIMENTAL
Intervention: Enalapril/hydrochlorothiazide (20/6 mg) daily
Number of subjects: 174

Group type: COMPARATOR
Intervention: Atenolol (50 mg) daily
Number of subjects: 174
Study: 8593194

Group type: EXPERIMENTAL
Intervention: stabilized 0.454% stannous fluoride dentifrice
Number of subjects: 328

Group type: COMPARATOR
Intervention: 0.243% sodium fluoride control
Number of subjects: 328
Study: 2503631

Group type: COMPARATOR
Intervention: Glucose infusion (N=13)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Lipid infusion (N=11)
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Amino acid infusion (N=17)
Number of subjects: 51

Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) (N=10)
Number of subjects: 51
Study: 797067

Group type: EXPERIMENTAL
Intervention: Xenon-arc photocoagulation treatment
Number of subjects: 100

Group type: COMPARATOR
Intervention: Untreated eyes
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: Treated eyes
Number of subjects: 100
Study: 31742849

Group type: EXPERIMENTAL
Intervention: MLAM-IV
Number of subjects: 120

Group type: COMPARATOR
Intervention: LAM-IV
Number of subjects: 120
Study: 31805902

Group type: EXPERIMENTAL
Intervention: Intervention group 1 (changes in school environment)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group 2 (changes in menu and school environment)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (without intervention)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Intervention group 1 and 2
Number of subjects: 0
Study: 27790760

Group type: EXPERIMENTAL
Intervention: Strength Training (STR)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Circuit Training (CT)
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Indoor Hockey (HOC)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 40
Study: 25959708

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL) using the GlideScope Cobalt AVL video laryngoscope
Number of subjects: 21

Group type: COMPARATOR
Intervention: Direct Laryngoscopy (DL)
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Video Laryngoscopy (VL)
Number of subjects: 21
Study: 23533022

Group type: EXPERIMENTAL
Intervention: Maps with varying attributes of a residential drinking water hazard (level, proximity, prevalence, density)
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Belief in the problem's seriousness
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Perceived susceptibility
Number of subjects: 446
Study: 21346607

Group type: EXPERIMENTAL
Intervention: ABT‐925 50 mg QD
Number of subjects: 155

Group type: EXPERIMENTAL
Intervention: ABT‐925 150 mg QD
Number of subjects: 155

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 155
Study: 19731780

Group type: EXPERIMENTAL
Intervention: Listening to 20 minutes of relaxing music
Number of subjects: 0

Group type: COMPARATOR
Intervention: 20 minutes of bed rest
Number of subjects: 0
Study: 17356091

Group type: EXPERIMENTAL
Intervention: 200 mug of salbutamol
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control (no inhaled medication)
Number of subjects: 120
Study: 15375224

Group type: EXPERIMENTAL
Intervention: Gadobenate dimeglumine (0.2 mmol/kg)
Number of subjects: 47

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 47
Study: 11257264

Group type: EXPERIMENTAL
Intervention: Fluvastatin
Number of subjects: 356

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 356
Study: 9589535

Group type: EXPERIMENTAL
Intervention: High-dose methylprednisolone
Number of subjects: 40

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study: 7981459

Group type: EXPERIMENTAL
Intervention: Tamoxifen 20 mgs/day
Number of subjects: 2012

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2012
Study: 2531065

Group type: EXPERIMENTAL
Intervention: methacholine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: histamine
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: ipratropium bromide
Number of subjects: 15
Study: 922328

Group type: EXPERIMENTAL
Intervention: 500 IU vitamin D daily
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 2000 IU vitamin D daily
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study: 30221338

Group type: EXPERIMENTAL
Intervention: US-guided IBPB (group U)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PNS-confirmation IBPB (group N)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: US-guided, PNS-confirmed IBPB (dual guidance; group NU)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: PNS-guided IBPB (group N)
Number of subjects: 109
Study: 26714522

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI)
Number of subjects: 169

Group type: COMPARATOR
Intervention: Usual care (treatment-as-usual)
Number of subjects: 169
Study: 24706191

Group type: EXPERIMENTAL
Intervention: 12% poikilocapnic hypoxia
Number of subjects: 12

Group type: COMPARATOR
Intervention: Normoxia
Number of subjects: 12
Study: 22462372

Group type: EXPERIMENTAL
Intervention: Whole-body vibration (17 Hz, at 1.1 m x s(‐2) in the z‐axis) for 15 min after 14 min of rest at each altitude
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Whole-body vibration
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Low vibration intensity used in the study
Number of subjects: 10
Study: 19863739

Group type: EXPERIMENTAL
Intervention: Reduced-dose rocuronium (0.45 mg x kg(‐1))
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Standard-dose rocuronium (0.6 mg.kg(‐1))
Number of subjects: 105

Group type: EXPERIMENTAL
Intervention: Vecuronium (0.1 mg x kg(‐1))
Number of subjects: 105

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 105
Study: 17564674

Group type: EXPERIMENTAL
Intervention: Whole Body Vibration (WBV) at 30 Hz; 3.5 g (1 g=9.81 m.s2)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Control (no vibration)
Number of subjects: 7
Study: 16282676

Group type: EXPERIMENTAL
Intervention: Doxercalciferol at 35%, 50%, or 65% of paricalcitol dose for 6 weeks
Number of subjects: 27
Study: 12242054

Group type: EXPERIMENTAL
Intervention: 50 mg mifepristone
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 600 mg and 1200 mg mifepristone
Number of subjects: 30